Search

Teva Pharmaceutical Industries Ltd.

Gesloten

SectorGezondheidszorg

35.06 -1.04

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

34.82

Max

35.14

Belangrijke statistieken

By Trading Economics

Inkomsten

-112M

369M

Verkoop

-730M

4B

K/W

Sectorgemiddelde

23.022

64.641

EPS

0.53

Winstmarge

9.269

Werknemers

31,173

EBITDA

245M

877M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+17.59% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-209M

36B

Vorige openingsprijs

36.1

Vorige sluitingsprijs

35.06

Nieuwssentiment

By Acuity

7%

93%

1 / 340 Rangschikking in Healthcare

Teva Pharmaceutical Industries Ltd. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 aug 2026, 19:01 UTC

News
Correlated Moves

Ethereum is trading lower, reflecting a broader decline in correlated assets. It remains below its 20-day moving average amid routine market fluctuations.

1 aug 2026, 00:06 UTC

Social Media
News

TLT trades lower in after-market hours, reflecting a historically bearish period for bonds and targeting the $80 level amid rising interest rate expectations.

1 aug 2026, 00:06 UTC

News

Geopolitical tensions with Iran have boosted the United States Oil Fund LP, following President Trump's ordered military offensive in response to attacks on U.S. troops.

1 aug 2026, 00:06 UTC

News

Ameriprise Financial Inc shares are lower in after-market trading, despite strong second-quarter revenue of $4.90 billion and adjusted EPS of $11.07.

1 aug 2026, 00:02 UTC

News

UBS raised its price target on Hershey Co to $198, maintaining a Neutral rating. Shares are trading higher during after-market hours.

1 aug 2026, 00:02 UTC

News

Lattice Semiconductor shares are lower in after-market trading following a cautionary report citing declining sales and rising costs, with shares priced at $124.53.

1 aug 2026, 00:02 UTC

News

Snap Inc. shares rose to about $4.70 in after-market hours, supported by bullish options activity ahead of its August 3 earnings report.

1 aug 2026, 00:02 UTC

News
Social Media

NVIDIA Corp shares are lower in after-market hours amid broader market declines, despite recent strong performance relative to peers and a weekly gain.

1 aug 2026, 00:02 UTC

News

Lockheed Martin secured a $107.29 million Navy contract for VH-92A rotor blade design, boosting shares in after-market hours.

1 aug 2026, 00:02 UTC

News
Correlated Moves

JPMorgan Chase & Co shares are lower in after-market trading amid ongoing market rotation and rising bond yields affecting investor sentiment.

1 aug 2026, 00:02 UTC

News

KKR & Co Inc reported record Q2 revenue of $6.31 billion. Shares declined in after-market trading despite strong earnings and net income growth.

1 aug 2026, 00:02 UTC

News

Exponent Inc shares are trading lower in after-market hours after UBS lowered its price target to $72 while maintaining a Neutral rating.

1 aug 2026, 00:02 UTC

News

Bloom Energy Corp is declining in after-market hours amid a class action lawsuit alleging securities fraud and broader market pressures.

1 aug 2026, 00:01 UTC

News

Quantum Corp shares are higher in after-market trading, supported by positive developments in the quantum computing industry and strong investor interest in the sector.

1 aug 2026, 00:01 UTC

News

UBS raised its price target on Bright Horizons to $88, as shares gain in after-market trading following three sessions of declines.

1 aug 2026, 00:01 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and concerns over a failed clinical trial.

1 aug 2026, 00:01 UTC

News

Newell Brands Inc shares are lower in after-market hours amid overall market declines. The company entered a five-year credit facility of up to $800 million.

1 aug 2026, 00:01 UTC

News

UBS raised its price target on Valero Energy Corp to $355, contributing to shares' gain during after-market hours on Friday.

1 aug 2026, 00:01 UTC

News

UBS maintains Buy rating on Saia Inc, lowering price target to $504. Shares are higher in after-market trading following the adjustment.

1 aug 2026, 00:01 UTC

News

Alnylam Pharmaceuticals shares are lower in after-market hours, reflecting broader market declines despite a strong second-quarter revenue of $1.2 billion.

1 aug 2026, 00:01 UTC

News

American Electric Power reported Q2 earnings of $1.36 per share and raised its 2026 guidance to $6.25 to $6.55, driving shares higher in after-market hours.

1 aug 2026, 00:01 UTC

News

Clean Energy Fuels Corp is trading lower in after-market hours following a cautionary analysis highlighting its subpar revenue growth and high production costs.

1 aug 2026, 00:01 UTC

News

Chevron Corp has reached an accord with Iraq to invest in two oil fields, enhancing production capabilities. Shares are trading higher in after-market hours.

31 jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31 jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31 jul 2026, 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31 jul 2026, 23:46 UTC

News

3M shares declined in after-market trading amid concerns over insider selling by EVP Kevin H. Rhodes, who sold $1.3 million worth of stock.

31 jul 2026, 23:41 UTC

Social Media
News
Correlated Moves

Goldman Sachs shares declined in after-market trading amid broader market turmoil and hedge fund degrossing linked to losses on leveraged AI investments.

31 jul 2026, 23:41 UTC

News

JPMorgan Chase & Co. shares are lower in after-market trading following a note highlighting ongoing market rotation and challenges from rising long-term Treasury yields.

31 jul 2026, 23:36 UTC

News

Carvana shares declined in after-market trading following Citigroup's price target cut to $90, amid broader market weakness from Apple's disappointing guidance.

Peer Vergelijking

Prijswijziging

Teva Pharmaceutical Industries Ltd. Prognose

Koersdoel

By TipRanks

17.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 41.17 USD  17.59%

Hoogste 44 USD

Laagste 40 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Teva Pharmaceutical Industries Ltd. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Sentiment

By Acuity

1 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
help-icon Live chat